Literature DB >> 27391867

Current treatment options for esophageal diseases.

Jan Martínek1, Jun-Ichi Akiyama2, Zuzana Vacková3, Manuele Furnari4, Edoardo Savarino5, Teus J Weijs6, Elen Valitova7, Sylvia van der Horst8, Jelle P Ruurda8, Lucas Goense8, George Triadafilopoulos9.   

Abstract

Exciting new developments-pharmacologic, endoscopic, and surgical-have arisen for the treatment of many esophageal diseases. Refractory gastroesophageal reflux disease presents a therapeutic challenge, and several new options have been proposed to overcome an insufficient effectiveness of proton pump inhibitors. In patients with distal esophageal spasm, drugs and endoscopic treatments are the current mainstays of the therapeutic approach. Treatment with proton pump inhibitors (or antireflux surgery) should be considered in patients with Barrett's esophagus, since a recent meta-analysis demonstrated a 71% reduction in risk of neoplastic progression. Endoscopic resection combined with radiofrequency ablation is the standard of care in patients with early esophageal adenocarcinoma. Mucosal squamous cancer may also be treated endoscopically, preferably with endoscopic submucosal dissection. Patients with upper esophageal cancer often refrain from surgery. Robot-assisted, thoracolaparoscopic, minimally invasive esophagectomy may be an appropriate option for these patients, as the robot facilitates a good overview of the upper mediastinum. Induction chemoradiotherapy is currently considered as standard treatment for patients with advanced squamous cell carcinoma, while the role of neoadjuvant therapy for adenocarcinoma remains controversial. A system for defining and recording perioperative complications associated with esophagectomy has been recently developed and may help to find predictors of mortality and morbidity.
© 2016 New York Academy of Sciences.

Entities:  

Keywords:  Barrett's esophagus; distal esophageal spasm; esophageal carcinoma; esophagectomy; gastroesophageal reflux disease

Mesh:

Substances:

Year:  2016        PMID: 27391867     DOI: 10.1111/nyas.13146

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Radiofrequency Ablation for Dysplastic and Nondysplastic Barrett Esophagus.

Authors:  George Triadafilopoulos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-09

2.  Gene-expression signature may be useful for the prediction of lymph node metastasis in esophageal cancer.

Authors:  Yoshifumi Baba; Hideo Baba
Journal:  Ann Transl Med       Date:  2018-06

3.  Quantifying optical properties with visible and near-infrared optical coherence tomography to visualize esophageal microwave ablation zones.

Authors:  Ryan C Niemeier; Sevde Etoz; Daniel A Gil; Melissa C Skala; Christopher L Brace; Jeremy D Rogers
Journal:  Biomed Opt Express       Date:  2018-03-13       Impact factor: 3.732

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.